Search This Blog

Saturday, January 9, 2021

Grocery store pharmacies to help speed COVID-19 vaccinations

 Health officials across the U.S. are reaching out to grocery store pharmacies weeks earlier than planned to ask for help in administering COVID-19 vaccines amid a slower-than-expected rollout, The Wall Street Journal reported. 

Officials from South Carolina and Georgia reached out to grocery store chain Kroger this week, and the company has been giving vaccines to healthcare workers in its stores and in long-term care facilities in Alaska, West Virginia, Texas and Arkansas, the Journal reported Jan. 8.  

Kroger told the Journal it is exploring ways to hold large events in places like community centers and stadiums where it could vaccinate 600 to 800 people at a time. Giant Eagle, a grocery store chain based in Pittsburgh, said it is also discussing with states how to use spaces like fairgrounds and courthouses to set up vaccination sites. 

Most retail pharmacies were expected to start administering vaccines during the next phase of the vaccine rollout and have been hiring pharmacists and pharmacy technicians in preparation. 

Walgreens CEO Stefano Pessina told the Journal the company is able to give many more vaccines than it is. 

"We could do much more as a pharmacy chain if we had a certain degree of freedom," he said. 

Kroger's president of its healthcare business, Colleen Lindholz, told the Journal the company is only receiving a small portion of the number of vaccines it has the ability to handle. The company's pharmacy chain provides about 200,000 doses of the flu vaccine weekly  during flu season, and has so far given about 4,500 doses of COVID-19 vaccinations in total. 

Rite Aid, the third-largest pharmacy chain in the U.S., told the Journal that more states are reaching out to ask for help with vaccinations. The company  recently started administering vaccines to healthcare workers in New Jersey, Philadelphia, New York City and Delaware. 

https://www.beckershospitalreview.com/pharmacy/health-officials-ask-grocery-store-pharmacies-to-help-speed-covid-19-vaccinations.html

Brazil health regulator says application for Sinovac vaccine lacks info

 Brazilian health authority Anvisa said on Saturday that the application from São Paulo-based medical center Butantan for emergency use of a COVID-19 vaccine developed by China's Sinovac Biotech lacks some relevant information for the analysis.

Anvisa said in a statement that Butantan did not inform, for instance, the age, gender or comorbidities of participants in trials with Sinovac's CoronaVac vaccine. The application also missed data on the vaccine's immunogenicity on Phase III trials and some details on the number of participants, the health authority said.

Butantan delivered its application on Friday.

Brazil's state-run Fiocruz Institute also submitted on Friday an application for emergency use of the AstraZeneca COVID-19 vaccine. Anvisa said on Saturday that all required information has been delivered.

https://www.marketscreener.com/quote/stock/SINOVAC-BIOTECH-LTD-5714593/news/Sinovac-Biotech-Brazil-health-regulator-says-application-for-Sinovac-vaccine-lacks-information-32152687/

Buy Solid Biosciences (SLDB) on Weakness - Chardan Capital

 Chardan Capital Markets analyst Gbola Amusa reiterated a Buy rating and $12.50 price target on Solid Biosciences (NASDAQ: SLDB)

https://www.streetinsider.com/Analyst+Comments/Buy+Solid+Biosciences+%28SLDB%29+on+Weakness+-+Chardan+Capital/17801748.html

Jefferies Upgrades CVS Health (CVS) to Buy; COVID Vax Near-Term Boost

 Jefferies analyst Brian Tanquilut upgraded CVS Health (NYSE: CVS) from Hold to Buy

https://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+CVS+Health+%28CVS%29+to+Buy%3B+COVID+Vaccine+to+Provide+Near-Term+Boost/17799163.html

Illumina, Helix to Assess, Survey US Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7)

 Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. The combination of Illumina’s sequencing technology and expertise and Helix’s national COVID-19 testing footprint will significantly expand the country’s existing surveillance efforts to detect and characterize emerging variants of SARS-CoV-2.

The collaboration has already demonstrated results – identifying 51 of the first 54 cases of B.1.1.7, the highly transmissible variant first found in the UK, reported in the US. Over the past several weeks, Helix has analyzed recent positive samples and identified those with ‘S gene dropout’ on their diagnostic PCR assay, indicating the potential presence of the emerging B1.1.7 variant in different regions in the US. Illumina then sequenced a subset of these ‘S gene dropout’ samples using Illumina’s COVIDSeq Test, which identified the B.1.1.7 variant in 4 samples from California and Florida.

“Genomic surveillance is essential in fighting the pandemic. Illumina is pleased to partner with the CDC and Helix to provide accurate sequencing that can contribute to rapidly scaling genomic surveillance in the US to better understand the presence of B.1.1.7 and other variants as they emerge in our communities,” said Dr. Phil Febbo, M.D., Chief Medical Officer of Illumina.

https://www.businesswire.com/news/home/20210105006007/en/Illumina-and-Helix-Collaborate-to-Assess-Prevalence-of-New-SARS-CoV-2-UK-Variant-B.1.1.7-in-the-US-and-Develop-National-Surveillance-Infrastructure

Novavax Strikes Another Coronavirus Vaccine Supply Deal

 Novavax, Inc. 

NVAX 4.93% shares are higher Friday following a coronavirus vaccine supply deal the company announced with the Australian government.

Deal Sealed: Novavax, based in Gaithersburg, Maryland, said late Thursday the Australian government has executed a purchase agreement to buy 51 million doses of NVX-CoV2373, the company's coronavirus vaccine candidate, with an option to buy an additional 10 million doses. This follows an agreement in principle the parties announced in November.

Upon the vaccine candidate hitting efficacy and safety goals in ongoing pivotal trials, the company will work with the Australian drug regulator to obtain product approvals. The company expects to deliver the initial doses by mid-2021.

Is this timeline a practically achievable target, given the delays the company experienced in the start of the late-stage trial? Here's a look at where Novavax' vaccine program stands.

The Wait Extends: NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, created using the company's recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein. It's adjuvanted with Novavax's patented saponin-based Matrix-M to enhance the immune response and stimulate high levels of neutralizing antibodies.

The company's vaccine program is federally funded, with CEPI, the Department of Defense and the Operation Warp Speed program extending financial support to the tune of $1.6 billion to bring the program to fruition.


In early August 2020, Novavax reported positive interim readout from the Phase 1 portion of the Phase 1/2 trial evaluating the investigational vaccine. Both dose levels of NVX-CoV2373 — 5 mcg and 25 mcg — generated peak geometric mean titer greater than 1:3,300, and the vaccine-induced neutralization in 100% of participants. Following the data readout, Novavax initiated the Phase 2 portion of the trial in late August.

Interim readout from the study was scheduled to be released in the fourth quarter of 2020. In late November, the company said preliminary blinded data on NVX-CoV2373 in older adults needed to proceed to Phase 3 was reviewed by the FDA, and additional data are expected to be unblinded in the first quarter of 2021 and targeted for publication.

NVX-CoV2373 is also currently being evaluated in two pivotal Phase 3 trials; A trial in the U.K that completed enrollment in November; and the PREVENT-19 trial in the U.S. and Mexico that began in December. The U.S. and Mexico leg of the trial was delayed multiple times before going online in late December.

A Phase 2b trial is underway in South Africa.

From Thursday's update, it looks like a readout from the event-driven, late-stage trials should be coming over the next couple of months — a seemingly ambitious timeline. In the interim, Novavax announced multiple production and supply agreements.

"We believe this part of Novavax' COVID-19 program, as well as its collaborations with key strategic regional players in Asia, bolsters our view that the company is very competitive versus much larger COVID-19 vaccine players, and has a comprehensive global vaccine distribution plan that remains underappreciated," HC Wainwright analyst Vernon Bernardino said in a December note.

The yet-to-be-proven vaccine program led to a huge run-up in Novavax stock in 2020, as it ended as one of the best performing biopharma of the year. In 2020, the stock appreciated over 2,700%, and has added another 15% in the new year.

https://www.benzinga.com/general/biotech/21/01/19077613/novavax-strikes-another-coronavirus-vaccine-supply-deal-where-does-the-companys-program-stand

December Job Losses As COVID-19 Ravages Restaurants, Bars

 The U.S. economy shed jobs for the first time in eight months in December as the country buckled under an onslaught of COVID-19 infections, suggesting a significant loss of momentum that could temporarily disrupt the recovery from the pandemic.

The plunge in nonfarm payrolls reported by the Labor Department on Friday was concentrated in the coronavirus-sensitive leisure and hospitality sector, which lost nearly half a million jobs. But with other industries including retail, manufacturing and construction performing better, the economy is unlikely to tip back into recession.

Nearly $900 billion in additional pandemic relief approved by the government in late December will probably provide a backstop. More fiscal stimulus is expected now that Democrats have gained effective control of the U.S. Senate, boosting the prospects for President-elect Joe Biden’s legislative agenda. There is also optimism the rollout of coronavirus vaccines will be better coordinated under the incoming Biden administration.

Congress on Thursday formally certified Biden’s victory in the Nov. 3 election, hours after hundreds of President Donald Trump’s supporters stormed the U.S. Capitol. The employment report is one of the final scorecards delivered during the Trump presidency and stands as a reminder of the tumultuous economic crisis that marked his last months in office.

“This is a pause in the recovery, not a full-on stall,” said Chris Low, chief economist at FHN Financial in New York.

Payrolls decreased by 140,000 jobs last month, the first decline since April, after increasing by 336,000 in November. The economy has recovered 12.4 million of the 22.2 million jobs lost during the pandemic. Economists polled by Reuters had forecast 77,000 jobs would be added in December.

COVID-19 cases in the United States have jumped to more than 21 million, with the death toll exceeding 357,000, according to a Reuters analysis.

The leisure and hospitality sector lost 498,000 jobs last month, with employment at bars and restaurants tumbling 372,000, accounting for three quarters of the drop. Restaurants and bars in many states, including New York and California, were shut during the holidays to slow the spread of the virus. Excluding the leisure and hospitality sector, payrolls rose at roughly the same pace as in November.

There were also decreases in private education jobs as many universities and colleges closed after the Thanksgiving holiday. Government employment declined for a fourth straight month, with losses spread across federal state and local governments.

But retail employment rose by 121,000 jobs. Factories hired 38,000 workers and construction payrolls increased by 51,000 jobs. There were also gains in employment in professional and business services, transportation and warehousing, health care and wholesale trade industries.

Weak payrolls joined soft consumer confidence and spending in underscoring the brutal impact of the coronavirus on the economy, which sank into recession in February. The data increases the likelihood of another rescue package by March.

Stocks on Wall Street were trading mostly higher on hopes of more government money. The dollar rose against a basket of currencies. U.S. Treasury prices were trading mostly lower.

SOME SILVER LININGS

With the virus hollowing out lower-wage industries, average hourly earnings surged 0.8% after gaining 0.3% in November. The average workweek dipped to 34.7 hours from 34.8 in November.

Though the unemployment rate was unchanged at 6.7% in December, that was because of people misclassifying themselves as being “employed but absent from work.” Without this misclassification, the jobless rate would have been about 7.3%.

Despite last month’s job losses, the labor market is steadily improving. A broader measure of unemployment, which includes people who want to work but have given up searching and those working part-time because they cannot find full-time employment, fell to 11.7% from 12.0% in November.

The number of people who have permanently lost their jobs declined by 348,000 to 3.370 million. That was the biggest drop since December 2010. Still, it will probably take years for the scars from the pandemic to heal. Nearly 4 million Americans have been unemployed for more than six weeks, accounting for 37.1% of the jobless in December.

“These scarring effects pose downside risks to the recovery and could lead to elevated long-term unemployment and weakened labor market attachment for years to come,” said Lydia Boussour, a senior U.S. economist at Oxford Economics in New York.

The labor force participation rate, or the proportion of working-age Americans who have a job or are looking for one, remains at a depressed 61.5%. The employment-to-population ratio, seen as a measure of an economy’s ability to create jobs, held at a low 57.4%.

Economists are optimistic employment will rebound in the months ahead and accelerate through 2021 amid expectations for increased inoculations and additional fiscal stimulus, including more infrastructure spending under the Biden administration.

“Savings are burning a hole in many people’s pockets after having to avoid travel, in-person dining and entertainment for nearly a year,” said Sarah House, a senior economist at Wells Fargo Securities in Charlotte, North Carolina. “Hiring could ramp up quickly once COVID cases are more under control.”

Many economists have upgraded their 2021 growth estimates following the recent relief package and two runoff elections in Georgia this week that gave Democrats effective control of the U.S. Senate. Biden’s party maintained its control of the U.S. House of Representatives in the Nov. 3 election.

https://www.oann.com/u-s-economy-suffers-job-losses-as-covid-19-ravages-restaurants-bars/